CYP3A5 and hepatocellular carcinoma: The CYP2D6*10 mutant homozygous genotype has been shown to be 2.8 times less frequent in HCC patients than in controls, whereas the CYP2C9*3 and CYP3A5*3 polymorphisms have been shown to cause changes in enzyme activity [290].